IPPRITT - U1248
Individual Profiling and Prevention of Risks with Immunosuppressive Therapies and Transplantation

The unit conducts pharmacokinetics (PK) and pharmacogenetics (PG) research on immunosuppressive drugs (IS), both on an experimental and a clinical basis, in order to :

• Identify the response factors to the IS chemotherapies, whether they are of PG (concerning graft’s or host’s transporters, metabolic enzymes, therapeutic targets), PK (graft’s or host’s exposure indices) or environmental (associated diseases, drug interactions, food, etc.) nature.
• Validate clinically the concept of personalized treatment based on the main response factors identified, together with ancillary pharmaco-economic evaluations.
• Have a better understanding of the therapeutic and side effects of drugs in the allograft natural history through pharmaco-epidemiological studies.

Partnerships

Active national university collaboration:

• With several interdisciplinary clinical and pharmacological teams in most French and Belgian university hospital transplantation centers, within the scope of clinical research protocols (PHRC inter-regional and national).
• With nephrologists from the University Hospital Center of Toulouse within the framework of the study of pharmacogenetics and pharmacokinetics/ pharmacodynamics in transplantation.
• With several pediatric nephrologists in Southern France (Lyon, Toulouse, Marseille, Bordeaux, Montpellier, Clermont-Ferrand, Limoges) within the scope of optimization of immunosuppressive treatments for children with auto-immune diseases.

Current international university collaboration:

• Collaboration with the transplantation centre of Erasmus Hospital, Brussels, within the framework of pulmonary transplantation research protocols.
• International scientific collaboration on experimental (University of California at San Francisco) and clinical (Erasmus Medical Centre, Rotterdam) pharmacogenetic research projects.

International industrial partners:

• Contracts with the pharmaceutical industry (Roche Pharma, Novartis, Wyeth, Astellas) for the development of adaptation tools for immunosuppressive drugs’ dosage.
• Contracts with the diagnostic industry.